Stimulating pharmaceutical research and development for neglected diseases

Health Policy

Volumn 64, Issue 1, 2003, Pages 75-88

  Mrazek, Monique F ^a   Mossialos, Elias ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Neglected diseases; Pharmaceutical research and development; Public private partnerships

Indexed keywords

BCG VACCINE; CHLOROQUINE; DIETHYLCARBAMAZINE; EFLORNITHINE; FANSIDAR; HALOFANTRINE; IVERMECTIN; MEFLOQUINE; OXAMNIQUINE; PENTAMIDINE; PRAZIQUANTEL; QUININE; SURAMIN;

AFRICAN TRYPANOSOMIASIS; ANTIBIOTIC RESISTANCE; CHAGAS DISEASE; DENGUE; DEVELOPING COUNTRY; DRUG INDUSTRY; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; MALARIA; MEDICAL RESEARCH; MORBIDITY; MORTALITY; NON PROFIT ORGANIZATION; ONCHOCERCIASIS; PUBLIC HEALTH; REVIEW; SCHISTOSOMIASIS; TOXICITY; TUBERCULOSIS; VISCERAL LEISHMANIASIS;

EID: 0037375916     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(02)00138-0     Document Type: Article

References (58)

1. Attaran A., Kremer M., Sachs J., Sievers. A tax credit for sales of HIV, Tuberculosis and Malaria vaccines. 2000;Center for International Development, Harvard University, Boston. Available from http://post.economics.harvard.edu/faculty/kremer/vaccine.html (retrieved 2001 July 15).
2. Creating global markets for neglected drugs and vaccines: a challenge for public-private partnership. 2000;The Institute, San Francisco.
3. Kremer M. Stimulating R&D on vaccines for AIDS, tuberculosis and malaria: the role of tax credits for sales of vaccines to non-profit organizations. 2000;. Available from http://post.economics.harvard.edu/faculty/kremer/papers/salesvsrnd.pdf (retrieved 2001 July 15).
4. Vaccines for the New Millennium Act (US). H. R. 1504. 107th Congress, 1st Session, April 4, 2001.
5. Tackling the diseases of poverty: meeting the Okinawa/Millennium targets for HIV/AIDS, tuberculosis and malaria. 2001;PIU, Cabinet Office, London.
6. Special theme - public private partnerships for vaccines and drugs. Bulletin of World Health Organization. 79:2001;693-801.
7. Wellcome Trust. Wellcome Trust funds partnerships between scientists to combat tropical diseases (Press release) 10 February, 1998. Available from http://www.welcome.ac.uk/en/1/awtprerela98n61.html (retrieved 2001 Aug 20).
8. Morel C. TDR: a knowledge management and network organization. 2001;TDR, Geneva. http://www.who.int/tdr/publications/publications/pr15.htm (retrieved 2001 Aug 12).
9. Veekan H., Pecoul B. Drugs for 'neglected diseases': a bitter pill. Tropical Medicine and International Health. 5:2000;309-311.
10. World Health Organization. The World Health Report 2000. Health Systems: Improving Performance. Geneva: WHO, 2000.
11. Williams A. Science or marketing at WHO? A commentary of World Health 2000. Health Economics. 10:2001;93-100.
12. McKee M. Measuring the efficiency of health systems. British Medical Journal. 323:2001;295-296.
13. Special Programme for Research and Training in Tropical Diseases (TDR). Chaing Mai declaration on dengue/dengue haemorhagic fever. TDR News 2001; 64. Available from http://www.who.int/tdr/publications/tdrnews/news64/declaration.htm (retrieved 2001 Aug 21).
14. Paredes R., Laguna F., Clotet B. Leishmaniasis in HIV-infected persons: a review. Journal of the International Association of Physicians in AIDS Care. 3:1997;22-39.
15. Harries A.D., Hargreaves N.J., Kemp J., et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet. 357:2001;1519-1523.
16. Center for Disease Control (US). Box 23: Drug-Resistant Malaria. 2001. Available from http://www.cdc.gov/ncidod/emergplan/box23.htm (retrieved Sept 10, 2001).
17. World Health Organisation. Anti-tuberculosis Drug Resistance in the World. Report no. 2: Prevalence and Trends. Geneva:WHO, 2000. Available from http://www.who.int/emcdocuments/antimicrobial_resistance/ whocdstb2000278c.html. (retrieved 2001 Sept 10).
18. Goodman C.A., Mills A.J. The evidence base on the cost-effectiveness of malaria control measures in Africa. Health Policy and Planning. 14:1999;301-312.
19. Special Programme for Research and Training in Tropical Diseases (TDR). Dengue/dengue haemorrhagic fever in the Americas. TDR News 2001;64. Available from http://www.who.int/tdr/publications/tdrnews/news64/dengue.htm (retrieved 2001 Aug 21).
20. WHO medicines strategy: framework for action in essential drugs and medicines policy 2000-2003. 2000;WHO, Geneva.
21. Whitehead M., Dahlgren G., Evans T. Equity and health sector reforms: can low-income countries escape the medical poverty trap? Lancet. 358:2001;833-836.
22. Commission of the European Communities. Accelerated action targeted at major communicable diseases within the context of poverty reduction. Communication of the Commission to the Council and the European Parliament. Brussels, 20.9.2000. COM(2000) 585 final, 2001.
23. World Health Organisation and World Trade Organisation Secretariats. Report of the workshop on differential pricing and financing of essential drugs. Final report of the proceedings. April 8-11, Høsbjør, Norway, 2001. Available from http://www.wto.org/english/tratop_e/tn_hosbjor_e.htm (retrieved 2001 Sept 3).
24. Laing R.O., Hogerzeil H.V., Ross-Degnan D. Ten recommendations to improve use of medicines in developing countries. Health Policy Planning. 16:2001;13-20.
25. Letvin N.L., Bloom B.R., Hoffman S.L. Prospects for vaccines to protect against AIDS, tuberculosis and malaria. Journal of the American Medical Association. 285:2001;606-611.
26. Special Programme for Research and Training in Tropical Diseases (TDR). New lease of life for ressurection drug. TDR News 2001;64. Available from http://www.who.int/tdr/publications/tdrnews/news64/eflornithine.htm (retrieved 2001 Aug 21).
27. Special Programme for Research and Training in Tropical Diseases (TDR). First vaccine trial against visceral leishmaniasis. TDR News 2001;64. Available from http://www.who.int/tdr/publications/tdrnews/news64/leish.htm (retrieved 2001 Aug 21).
28. World Health Organisation. Dengue and Dengue Haemorrhagic Fever. Fact Sheet 117, 1998. Available from http://www.who.int/inf-fs/en/fact117.html (retrieved 2001 Sept 10).
29. Beers M.H., Berkow B. The merck manual of diagnosis and therapy. 17th ed. 1999;Merck & Co Inc, Whitehouse Station NJ. Available from http://www.merck.com/pubs/mmanual/ (retrieved 2001 Sept 9).
30. Bishai W. Rising tide of multidrug resistant tuberculosis in developing countries: can anything be done? A report from a Conference Entitled: Community Based Approaches to the Treatment and Control of Multi-Drug Resistant Tuberculosis, April 4-5, Cambridge, MA, 1998. Available from http://hopkins-id.edu/diseases/tb/tb_bishai.html (retrieved 2000 Aug 15).
31. World Health Organisation. World Health Organization Report on Infectious Diseases: Removing Obstacles to Healthy Development. Geneva: WHO, 1999. Available from http://www.who.int/infectious-disease-report/pages/textonly.html (retrieved 2001 Sept 13).
32. Farmer P. The major infectious diseases in the world - to treat or not to treat? New England Journal of Medicine. 345:2001;208-210.
33. Pécoul B., Chirac P., Trouiller P., Pinel J. Access to essential drugs in poor countries: a lost battle? Journal of the American Medical Association. 281:1999;361-367.
34. Lanjouw J.O., Cockburn I.M. New pills for poor people? empirical evidence after GATT. World Development. 29:2001;265-289.
35. Trouiller P., Olliaro P.L. Drug development output from 1975 to 1996: what proportion for tropical diseases? International Journal of Infectious Diseases. 3:1999;61-63.
36. Mills A. Technology and Science as global public goods: Tackling priority diseases of poor countries. London School of Hygiene and Tropical Medicine, London, 2001. Available as PDF from http://wbln0018.worldbank.org/eurvp/web.nsf/Pages/Mills/$File/ MILLS.PDF (retrieved 2001 July 20).
37. Global Forum for Health Research. Monitoring Financial Flows for Health Research. Global Forum for Health Research, Geneva, 2001.
38. Global Forum for Health Research. The 10/90 Report on Health Research. Global Forum for Health Research, Geneva, 2002.
39. Reich R.M. The global drug gap. Science. 287:2000;1979-1981.
40. Special Programme for Research and Training in Tropical Diseases (TDR). An artesunate+sulphadoxine/pyrimethamine combination blister package being developed jointly. TDR News 2001; 64. Available from http://www.who.int/tdr/publications/tdrnews/news64/blister.htm (retrieved 2001 Sept 11).
41. Special Programme for Research and Training in Tropical Diseases (TDR). Chorporguanil/dapsone (LAPDAP) mulitcentre phase III clinical trial under way in Africa. TDR News 2001;62. Available from http://www.who.int/tdr/publications/tdrnews/news62/lapdap.htm (retrieved 2002 June 12).
42. Wheeler C., Berkley S. Initial lessons from public-private partnerships in drug and vaccine development. Bulletin of the World Health Organization. 79:2001;728-734.
43. Buse K., Waxman A. Public-private health partnerships: a strategy for WHO. Bulletin of the World Health Organization. 79:2001;748-754.
44. Malaria Vaccine Initiative. Three malaria vaccine development donors join forces (press release). 22 June, 2001. Available from http://www.malariavaccine.org/files/emv-200106.htm (retrieved 2001 Sept 9).
45. Brugha R., Walt G. A global health fund: a leap of faith? British Medical Journal. 323:2001;152-154.
46. G8. G8: the final official notice. Genoa Summit Meeting, 2001. Available from http://genoa-g8.it/eng/attualita/primo_piano/primo_piano_13.hml (retrieved 2001 Sept 9).
47. Buse K., Walt G. Global public-private partnerships: part II - what are the health issues for global governance? Bulletin of the World Health Organization. 78:2000;699-709.
48. Inland Revenue. REV BN 16: New Tax Incentives for Drugs and Vaccines for Killer Diseases. London: Inland Revenue, 2001. Available from http://www.inlandrevenue.gov.uk/budget2001/revbn16.htm (retrieved 2001 Sept 9).
49. Kremer M. Creating Markets for New Vaccines. Part I: Rationale. Jaffe A.B., Lerner J., Stern S. Innovation Policy and the Economy. I:2001;National Bureau of Economic Research: MIT Press, Cambridge, Mass.
50. Govindaraj R, Reich MR, Cohen JC. World Bank Pharmaceutical Discussion Paper. Washington, DC: Human Development Network, The World Bank, 2000.
51. Burstall ML and Reuben B. Challenges of Drug Pricing and Availability in Developing Countries. Decision Resources 2002; Study #04, 12 April.
52. Haffner M.E. Orphan drugs: the United States experience. Drug Information Journal. 33:1999;565-568.
53. Kettler H.E. Narrowing the gap between provision and need for medicines in developing countries. 2000;Office of Health Economics, London.
54. HM Treasury and Inland Revenue. Increasing Innovation: A consultation Paper Budget 2001. London: Public Enquiry Unit, HM Treasury, 2001. Available from http://hm-treasury.gov.uk (retrieved 2001 Sept 9).
55. Bloom N, Griffith R, Van Reenen J. Do R&D Tax Credits Work? Evidence from an International panel of countries 1979-1994. Institute for Fiscal Studies, Working Paper No. 99/8, 1999.
56. Webber D., Kremer M. Perspectives on stimulating industrial research and development for neglected infectious diseases. Bulletin of the World Health Organization. 79:2001;735-741.
57. Bill Summary & Status for the 107th Congress. H.R. 1504. Thomas-US Congress. Available from http://thomas.loc.gov/ (retrieved 2002 June 12).
58. Waddington C. Don't be distracted from good routine immunization. GAVI Immunization Focus, March, 2001. Available from http://www.vaccinealliance.org/tex...etter/mar2001/idea_waddington.html (retrieved 2001 Aug 17).